February 3, 2022

Name of listed company: Chugai Pharmaceutical Co., Ltd.

Code number:

4519 (1st Section of Tokyo Stock Exchange)

Head office:

1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo

President & CEO:

Osamu Okuda

Inquiries to:

Toshiya Sasai

Head of Corporate Communications Dept.

Tel: +81-(0)3-3273-0554

Notice of Changes in Representative Directors and Directors

Chugai Pharmaceutical Co., Ltd. (the "Company") announces changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting scheduled on March 29, 2022.

1. Change in Representative Directors

(1) Reason for Change

Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting our growth strategy "TOP I 2030" under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors.

(2) Retiring Representative Directors

Name

Current Title

Tatsuro Kosaka

Representative Director, Chairman

Motoo Ueno

Representative Director, Deputy Chairman

  • Tatsuro Kosaka and Motoo Ueno are expected to be appointed as Senior Advisors.
  • Osamu Okuda is expected to be appointed as Chairman of the Board of Directors.
  1. Effective Date March 29, 2022

2. Change in Directors

  1. Newly Appointed Directors

Name

New Title

Current Title

Director, Executive Vice President

Executive Vice President

Supervisory responsibility for Project &

Supervisory responsibility for Project &

Hisafumi Yamada

Lifecycle Management (R&D), Research,

Lifecycle Management (R&D), Research,

Translational Research, Clinical

and Translational Research

Development, and Pharmaceutical

Technology

Director, Executive Vice President

Executive Vice President

Chief Financial Officer (CFO)

Chief Financial Officer (CFO)

Toshiaki Itagaki

Supervisory responsibility for Finance &

Supervisory responsibility for Finance &

Accounting, Corporate Communication, and

Accounting, Corporate Communication,

Purchasing

Purchasing, and Digital Transformation

Head of Finance Supervisory Div.

Head of Finance Supervisory Div.

  1. Effective Date March 29, 2022

###

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 03 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2022 08:08:07 UTC.